ライフサイエンスコーパス: omalizumab

1 monstrated and improved by anti-IgE therapy (omalizumab).

2 long-term use of asthma therapies, including omalizumab.

3 ilar reaction profile to those not receiving omalizumab.

4 rkers of asthma severity predict response to omalizumab.

5 t, we evaluated all SM patients treated with omalizumab.

6 oups of patients most likely to benefit from omalizumab.

7 severe persistent asthma receiving long-term omalizumab.

8 bserved after subcutaneous administration of omalizumab.

9 els was observed in subjects challenged with omalizumab.

10 ting antihistamines and the off-label use of omalizumab.

11 hange predict the response to treatment with omalizumab.

12 kely to benefit from adjunctive therapy with omalizumab.

13 blocked by the therapeutic anti-IgE antibody omalizumab.

14 ly to mepolizumab regardless of prior use of omalizumab.

15 eosinophilic asthma previously treated with omalizumab.

16 line with the established safety profile of omalizumab.

17 re dose dependent and highest with 300 mg of omalizumab.

18 nic spontaneous urticaria (CSU) treated with omalizumab.

19 ody that binds IgE with higher affinity than omalizumab.

20 ld setting, sponsored by the manufacturer of omalizumab.

21 molecular insights for controlling asthma by omalizumab.

22 opulation of pregnant women not treated with omalizumab.

23 a underline a functional activity similar to omalizumab.

24 ent in inhibiting IgE:CD23 interactions than omalizumab.

25 al use of the therapeutic anti-IgE antibody, omalizumab.

26 e are anecdotal reports regarding the use of omalizumab.

27 therapy (GBT) in the absence and presence of omalizumab.

28 vement in angioedema-burdened days/week with omalizumab (0.3) vs placebo (1.1).

29 for GLACIAL) or a UAS7 = 0 (11.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg

30 Omalizumab 150 mg does not result in clinically meaningf

31 .8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg

32 e inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks.

33 Omalizumab 300 mg results in clinically meaningful impro

34 a (CSU) patients (n = 113) were treated with omalizumab 300 mg/4 weeks for 12 weeks, when their treat

35 e, 68 completed the 28-week treatment phase (omalizumab, 35; placebo, 33).

36 1.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [pla

37 zumab reported a UAS7 </= 6 (26.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg

38 .3% [placebo] for ASTERIA I; 26.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg

39 5.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [pla

40 6.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [pl

41 6.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [pl

42 Omalizumab, a clinically approved therapeutic antibody,

43 Omalizumab, a humanized recombinant monoclonal anti-IgE

44 Omalizumab, a monoclonal antibody to IgE, improves asthm

45 Omalizumab, a recombinant anti-IgE antibody, effectively

46 onse to allergen challenge were treated with omalizumab according to the approved dosing table.

47 Continuation of omalizumab after long-term treatment results in continue

48 Omalizumab allows subjects with peanut allergy to be rap

49 Omalizumab, an anti-IgE antibody, is used to treat patie

50 been clinically validated by the approval of omalizumab, an anti-IgE mAb, for patients with chronic s

51 Omalizumab, an anti-IgE mAb, is the first targeted biolo

52 Omalizumab, an anti-immunoglobulin E monoclonal antibody

53 recurrence of angioedema was 57-63 days with omalizumab and <5 days with placebo.

54 s were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).

55 s to examine a potential association between omalizumab and cardiovascular (CV)/cerebrovascular (CBV)

56 strated that immune complexes formed between omalizumab and IgE can induce both skin inflammation and

57 estionnaire (ACQ)-5 score >=1.5 discontinued omalizumab and immediately commenced mepolizumab 100 mg

58 As the underlying mechanisms of omalizumab and mepolizumab therapy are distinct, it is r

59 [5.7] and 16.6 [7.3]) score were high in the omalizumab and placebo group, respectively.

60 ces in rates of asthma exacerbations between omalizumab and placebo groups during the 16-week inhaled

61 osteroid treatment were 0.066 and 0.147 with omalizumab and placebo, respectively, representing a rel

62 inatal outcomes in pregnant women exposed to omalizumab and their infants.

63 uced the rate of exacerbations by 57% (prior omalizumab) and 47% (no prior omalizumab) vs placebo.

64 Organization Well-being Index was 10.0 (5.5, omalizumab) and 7.7 (5.3, placebo), which increased abov

65 The two biologic therapies, anti-IgE (omalizumab) and anti-IL-5 antibodies (mepolizumab), are

66 developed an Fc-engineered mutant version of omalizumab, and demonstrated that this mAb is equally po

67 ding interactions to FcepsilonRIalpha, Her2, omalizumab, and spA.

68 tly reduced in whole blood samples from both omalizumab- and placebo-treated subjects.

69 lacebo] for ASTERIA II; and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for GLACIAL) or a UAS7 =

70 lacebo] for ASTERIA II; and 33.7% [300 mg of omalizumab] and 4.8% [placebo] for GLACIAL).

71 .0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8% [7

72 .7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II; and 52.

73 .0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [placebo] for ASTERIA II; and 33.7

74 .0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [placebo] for ASTERIA I; 15.9% [75

75 The efficacy of omalizumab (anti-IgE) and increased IgE levels in patien

76 (6-17 years, n = 413) enrolled in a trial of omalizumab (anti-IgE) underwent 16S rRNA profiling.

77 interaction with FcepsilonRIalpha, anti-IgE omalizumab, antigen, and superantigen protein A (spA) by

78 Omalizumab appears to be a promising treatment option in

79 Mepolizumab and omalizumab are treatments for distinct but overlapping s

80 Biologicals, including omalizumab, as well as corticosteroids, cyclophosphamide

81 dosing with placebo or 75, 150, or 300 mg of omalizumab (ASTERIA I: n = 318, 24 weeks; ASTERIA II: n

82 Omalizumab at 150 and 300 mg every 4 weeks was shown to

83 onstrated that this mAb is equally potent as omalizumab at blocking IgE-mediated allergic reactions,

84 ree examples, biologics such as dupilumab or omalizumab become reliable and efficient therapeutic opt

85 nd to evaluate the effects of administrating omalizumab before and during the infection.

86 Adverse events were generally low, with omalizumab being well tolerated by most patients, includ

87 mutant IgE-Fc fragment that is resistant to omalizumab binding.

88 Omalizumab binds IgE and prevents its engagement with Fc

89 Omalizumab binds to free IgE, which lowers free IgE leve

90 eshold (<13) from Week 4 and throughout with omalizumab but not placebo treatment.

91 e increased in washed cell preparations from omalizumab- but not placebo-treated subjects.

92 Overall, our data indicate that omalizumab can induce skin inflammation and anaphylaxis

93 , however, an absence of increased risk with omalizumab cannot be definitively established.

94 se patterns by using data from the 3 pivotal omalizumab CIU/CSU trials.

95 s were 6.66 (101 patients/15,160 PYs) in the omalizumab cohort and 4.64 (46 patients/9,904 PYs) in th

96 /CBV events in the omalizumab versus the non-omalizumab cohort.

97 and 4.64 (46 patients/9,904 PYs) in the non-omalizumab cohort.

98 did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy b

99 al anomalies among pregnant women exposed to omalizumab compared with a disease-matched unexposed coh

100 ti-human TLR4 mAbs or the anti-human IgE mAb omalizumab completely abolished ATI-induced allergic inf

101 after: 505.23 kU/L) and the presence of IgE-omalizumab complexes were observed after subcutaneous ad

102 ing this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVID

103 Omalizumab decreased the duration of RV infection (11.2

104 hildren with allergic asthma, treatment with omalizumab decreased the duration of RV infections, vira

105 Finally, omalizumab decreased the frequency of RV illnesses (risk

106 As new applications for omalizumab demand precise knowledge of the onset of effe

107 Use of 300 mg of omalizumab demonstrated best results in controlling CIU/

108 crystal structure of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to

109 Addition of omalizumab did not enhance IL-4/anti-CD40-induced IgE pr

110 levels, whereas intranasal administration of omalizumab did not enhance systemic total or allergen-sp

111 ted in non-responders and, more importantly, omalizumab did not significantly alter their expression

112 Omalizumab dosage per weight alone was strongly associat

113 the context of OIT and IgE-mediated disease, omalizumab dosages should be adjusted for body weight al

114 Our aim was to identify determinants of omalizumab dose-related efficacy in the context of OIT.

115 dy enrolled 250 women with asthma exposed to omalizumab during pregnancy.

116 ional Study of the Use and Safety of Xolair (omalizumab) during Pregnancy (EXPECT) pregnancy registry

117 ed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndU

118 clinical cohort of 181 patients treated with omalizumab-enabled oral immunotherapy at 3 centers.

119 Studies of omalizumab Fab binding in solution demonstrate the allos

120 Here we report the crystal structure of the omalizumab-Fab in complex with an IgE-Fc fragment.

121 We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in h

122 ubjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated.

123 Patients received omalizumab for at least 2 months before an initial food

124 review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU).

125 es in interaction were found between IgE and omalizumab for the pertuzumab VH variants.

126 : n = 322, 12 weeks) or placebo or 300 mg of omalizumab (GLACIAL: n = 335, 24 weeks).

127 more common in the omalizumab versus the non-omalizumab group (50% vs 23%).

128 Significantly more subjects in the omalizumab group (67%) had no protocol-defined exacerbat

129 1; area under the curve, 0.76) and the GBT + omalizumab group (P < .01; area under the curve, 0.65).

130 onth 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42

131 Participants in the omalizumab group had a significantly lower median per-pa

132 In the GBT + omalizumab group, younger age at recruitment, increased

133 orticosteroids and other controller(s), plus omalizumab (>=4 months).

134 Upon treatment with omalizumab, >75% of lesional signatures changed to refle

135 Overall, patients receiving omalizumab had a similar reaction profile to those not r

136 Subjects continuing omalizumab had significantly better asthma control (mean

137 Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17

138 Those that exacerbated on omalizumab had similar features with the exception of so

139 Omalizumab has been shown to improve the safety and feas

140 Omalizumab has positive short- and long-term safety prof

141 Our review indicates that omalizumab has substantial benefits in patients with var

142 Anti-IgE (omalizumab) has been used for the treatment of moderate-

143 The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with C

144 inical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published c

145 ific IgE and their interaction with blocking omalizumab-IgE complexes and free omalizumab levels in s

146 ses, total, allergen-specific IgE levels and omalizumab-IgE complexes as well as specific IgG levels

147 ERPRETATION: In multifood allergic patients, omalizumab improves the efficacy of multifood oral immun

148 lk oral immunotherapy (MOIT) with or without omalizumab in 55 patients with milk allergy treated for

149 nistration to assess the long-term safety of omalizumab in an observational setting, focusing predomi

150 d, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found signif

151 rimental models and by the successful use of omalizumab in individual patients with BP.

152 Data from two phase III clinical trials of omalizumab in patients with allergic asthma were examine

153 ted whether response rates to treatment with omalizumab in patients with CSU are linked to their base

154 needed to further clarify the involvement of omalizumab in relieving symptoms associated with the com

155 To assess the efficacy and safety of omalizumab in SM.

156 We sought to determine the efficacy of omalizumab in the management of patients with frequent e

157 strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-ref

158 ewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma th

159 Omalizumab, in treatment responders, reverted transcript

160 Omalizumab-induced reductions in pDC FcepsilonRIalpha le

161 To date, the mechanisms through which omalizumab induces adverse reactions are still unknown.

162 After omalizumab initiation, FEV1 improved at 6 months in resp

163 Omalizumab is a widely used therapeutic anti-IgE antibod

164 Omalizumab is an anti-IgE monoclonal antibody (mAb) appr

165 Omalizumab is an effective and well-tolerated treatment

166 Omalizumab is an established anti-IgE therapy for the tr

167 Omalizumab is an established treatment in other MC-drive

168 Omalizumab is approved as add-on therapy for CSU patient

169 Use of omalizumab is associated with reported side effects rang

170 cts, this desensitization is sustained after omalizumab is discontinued.

171 onists fail to control symptoms and/or using omalizumab is ineffective, not practical or unfunded.

172 Omalizumab is licensed for therapy in severe allergic as

173 h blocking omalizumab-IgE complexes and free omalizumab levels in serum (chi(2) = 65.84; degrees of f

174 and, together with the structure, reveal how omalizumab may accelerate dissociation of receptor-bound

175 Benefits of omalizumab may extend up to 2-4 years, and the majority

176 ion levels; this is consistent with observed omalizumab-mediated clinical improvement observed in pat

177 This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with

178 involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab).

179 We sought to investigate mechanisms by which omalizumab modulates immunity in the context of OIT and

180 8-75 years) were randomized to either 300 mg omalizumab (n = 20) or placebo (n = 10) administered s.c

181 delines-based asthma care (n = 89) or add-on omalizumab (n = 259).

182 Thirty-seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8).

183 Of the 91 patients randomized to omalizumab (n = 44) or placebo (n = 47) at baseline, 68

184 ergic asthma and who were being treated with omalizumab (n = 5007) or not (n = 2829) at baseline were

185 (N = 1071) were randomized to receive either omalizumab (n = 542) or placebo (n = 529).

186 otherapy to two to five foods, together with omalizumab (n=36) or placebo (n=12).

187 Ninety-one patients were randomized and 68 (omalizumab, n = 35; placebo, n = 33) completed the 28-we

188 ma without weals as a presentation of CU and omalizumab non-responders.

189 als were not randomised and received neither omalizumab nor oral immunotherapy.

190 compared the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and Fcepsil

191 Effects of omalizumab on IgE production by IL-4/anti-CD40-treated P

192 QGE031 has greater efficacy than omalizumab on inhaled and skin allergen responses in pat

193 The beneficial effects of administering omalizumab on reducing LRTSs and improving lung function

194 The effect of administering omalizumab on the response to rhinovirus was most pronou

195 and suppressed anaphylaxis more rapidly than omalizumab or ligelizumab.

196 sal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 w

197 tion of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allerge

198 Omalizumab or placebo was administered subcutaneously fo

199 subjects treated subcutaneously with either omalizumab or placebo.

200 in which subjects were randomized to receive omalizumab or placebo.

201 asthma exacerbation during the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PR

202 In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbati

203 zation scheme to continue their same dose of omalizumab or withdraw to placebo and were then followed

204 nd approximately 3-fold greater than that of omalizumab (P = .10) and 16-fold greater than that of pl

205 c subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1.

206 ergic asthma were randomized to subcutaneous omalizumab, placebo, or QGE031 at 24, 72, or 240 mg ever

207 bel milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 2

208 IgE effector axis, implying that sFceRI and omalizumab potentially inhibit each other in vivo.

209 ies, standard-dose nsAHs, updosed nsAHs, and omalizumab produced lower numbers of adverse events than

210 hought that the additional administration of omalizumab provided a good clinical response for an intr

211 Eight of the 9 patients receiving omalizumab reacted during desensitization, suggesting th

212 roportion of patients treated with 300 mg of omalizumab reported a UAS7 </= 6 (26.0% [75 mg of omaliz

213 IRIUS, with 13% and 33% previously receiving omalizumab, respectively.

214 ameters over time and the difference between omalizumab responder and nonresponder patients remain in

215 In the omalizumab responder patients, lung function parameters

216 not only transcriptional variations between omalizumab responders and non-responders, but also molec

217 rced expiratory volume in 1 second (FEV1) of omalizumab responders and nonresponders at 6 months.

218 Omalizumab response was assessed at the 6-month visit.

219 Omalizumab resulted in a marked reduction of CTTs in H(1

220 Here, we report omalizumab's effect on gene expression in skin biopsies

221 Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 tria

222 low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE.

223 mparable to the anti-IgE monoclonal antibody omalizumab, sFceRI is an inhibitor of the human innate I

224 ping combined with passive sensitization +/- omalizumab showed a dependency for basophil-bound IgE, s

225 Omalizumab significantly improved angioedema-specific Qo

226 Omalizumab significantly improved endoscopic, clinical,

227 defense mechanisms, it is unsurprising that omalizumab studies continue yielding biologic insights a

228 Omalizumab targets IgE, and IgE levels may be linked to

229 epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distin

230 p better markers to predict poor response to omalizumab therapy and alternative treatment strategies

231 als in children with persistent AA receiving omalizumab therapy and observational studies from the pa

232 Thus, omalizumab therapy is associated with signal improvement

233 At 10 years old, she began omalizumab therapy which improved asthma control.

234 Combining omalizumab therapy with milk OIT led to distinct alterat

235 the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is l

236 designed to prevent fall exacerbations with omalizumab therapy.

237 With omalizumab, there is currently still only one therapeuti

238 we examined factors that predict response to omalizumab to facilitate selection of patients most like

239 ld girl with severe asthma who switched from omalizumab to mepolizumab therapy and achieved good cont

240 After directly switching from omalizumab to mepolizumab, patients with uncontrolled se

241 n our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy

242 tration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases in IgE a

243 and the addition of oral corticosteroids and omalizumab to regular inhaled corticosteroid inhalation

244 ently, 23 (79%) of 29 subjects randomized to omalizumab tolerated 2000 mg of peanut protein 6 weeks a

245 6, a significantly greater proportion of the omalizumab-treated (30 [83%] of 36) versus placebo (four

246 4 per 1,000 person years [PYs]) than did non-omalizumab-treated patients (8.1 per 1,000 PYs).

247 Omalizumab-treated patients had a higher rate of CV/CBV

248 extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years.

249 y, representing a relative rate reduction in omalizumab-treated patients of 55% (95% CI, 32%-70%; P =

250 In omalizumab-treated patients, 27.1% (n/N = 78/288) had un

251 At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treat

252 re markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per

253 e initial desensitization day was 250 mg for omalizumab-treated subjects versus 22.5 mg for placebo-t

254 bjects (odds ratio, 0.57; P = .15), although omalizumab-treated subjects were exposed to much higher

255 action rates were not significantly lower in omalizumab-treated versus placebo-treated subjects (odds

256 sponders could maintain changes induced with omalizumab treatment and become more similar to the cont

257 These findings indicate that omalizumab treatment augments pDC IFN-alpha responses an

258 Our findings support omalizumab treatment in patients with severe H1-antihist

259 Omalizumab treatment increased rhinovirus- and influenza

260 ine whether reducing IgE levels in vivo with omalizumab treatment increases pDC antiviral IFN-alpha r

261 e X-ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic

262 To test whether omalizumab treatment to reduce IgE would shorten the fre

263 Benefits of omalizumab treatment were evident early (before week 4)

264 exacerbation-prone asthma before and during omalizumab treatment were stimulated ex vivo with rhinov

265 baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE

266 cts continuing or withdrawing from long-term omalizumab treatment.

267 he management of CSU in patients who require omalizumab treatment.

268 are largely unknown, but needed to optimize omalizumab treatment.

269 responders) were analysed over the course of omalizumab treatment.

270 Anti-IgE (omalizumab) treatment ablated this anaphylactic response

271 ins (IVIG), mepolizumab, methotrexate (MTX), omalizumab, upadacitinib and ustekinumab.

272 rmed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: sympto

273 placebo in both studies independent of prior omalizumab use, as shown by ACQ-5 and SGRQ scores.

274 s were also comparable irrespective of prior omalizumab use.

275 OCS use were comparable regardless of prior omalizumab use.

276 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving placebo (P < .0

277 Twenty-three subjects receiving omalizumab versus 1 subject receiving placebo passed the

278 trial compared the effects of administering omalizumab versus placebo to asthmatics in a randomized,

279 he mean changes from baseline at week 24 for omalizumab versus placebo were as follows: NPS, -1.08 ve

280 ny nose were also significantly improved for omalizumab versus placebo.

281 igher incidence rate of CV/CBV events in the omalizumab versus the non-omalizumab cohort.

282 cs, but severe asthma was more common in the omalizumab versus the non-omalizumab group (50% vs 23%).

283 ry objective was to evaluate the efficacy of omalizumab vs placebo at week 28 using the Chronic Urtic

284 Significant QoL improvements in the omalizumab vs placebo groups continued until Week 28, bu

285 by 57% (prior omalizumab) and 47% (no prior omalizumab) vs placebo.

286 Omalizumab was administered on 35th day and asthmatic at

287 Compared to placebo, omalizumab was also associated with decreased fear of su

288 Omalizumab was an effective treatment option for patient

289 ions to food dosing subsequent to weaning of omalizumab was associated with a greater ratio of specif

290 in children treated with GBT with or without omalizumab was associated with a higher saEPI along with

291 Discontinuation of omalizumab was associated with an increase in free IgE l

292 of patients in which adjunctive therapy with omalizumab was associated with attainment of sustained u

293 Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ra

294 At month 28, omalizumab was discontinued, and subjects passing an ora

295 Omalizumab was safely administered to a difficult-to-tre

296 Omalizumab was superior to placebo in improving CU-Q2oL

297 Omalizumab was then discontinued, and subjects continued

298 clonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patie

299 Continued food dose tolerance with omalizumab weaning was also documented.

300 trated that a therapeutic anti-IgE antibody, omalizumab, which inhibits IgE binding to FcepsilonRI, a

301 ral recent updates in the biology and use of omalizumab will be presented here, and others will be su

302 In patients receiving 300 mg of omalizumab with 24 weeks of treatment, median time to ac

303 0 ISM, 2 BMM, 1 SSM, and 1 ASM-AHN) received omalizumab with a median duration of 17 months (range: 1

304 The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Cali